HomeAI · summaries
Storia in 2 fonti
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
- ·
benzinga.com
What's Going On With Viking Therapeutics Stock Wednesday? - Viking Therapeutics (NASDAQ:VKTX)
Viking Therapeutics launches Phase 1 trial for obesity drug VK3019, a dual amylin/calcitonin receptor agonist. Read about the study.